1921
Volume 82, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

The spread of drug resistance is outpacing new antimalarial development and compromising effective malaria treatment. Combination therapy is widely implemented to prolong the effectiveness of currently approved antimalarials. To maximize utility of available drugs, periodic monitoring of drug efficacy and gathering of accurate information regarding parasite-sensitivity changes are essential. We describe a high-throughput, non-radioactive, field-based assay to evaluate antimalarial drug sensitivity of isolates from 40 Senegalese patients. Compared with earlier years, we found a significant decrease in chloroquine and in genotypic resistances (> 50% and > 65%, respectively, in previous studies) with only 23% of isolates showing resistance. This is possibly caused by a withdrawal of chloroquine from Senegal in 2002. We also found a range of artemisinin responses. Prevalence of drug resistance is dynamic and varies by region. Therefore, the implementation of non-radioactive, robust, high-throughput antimalarial sensitivity assays is critical for defining region-specific prophylaxis and treatment guidelines.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.2010.09-0470
2010-02-01
2019-01-21
Loading full text...

Full text loading...

/deliver/fulltext/14761645/82/2/228.html?itemId=/content/journals/10.4269/ajtmh.2010.09-0470&mimeType=html&fmt=ahah

References

  1. Kondrachine AV, Trigg PI, , 1997. Global overview of malaria. Indian J Med Res 106:: 3952. [Google Scholar]
  2. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI, , 2005. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434: 214217.[Crossref] [Google Scholar]
  3. Nosten F, White NJ, , 2007. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 77: 181192. [Google Scholar]
  4. World Health Organization, 2006. WHO guidelines for the treatment of malaria. Geneva: World Health Organization. [Google Scholar]
  5. Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, Ekala MT, Bouchier C, Esterre P, Fandeur T, Mercereau-Puijalon O, , 2005. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 366: 19601963.[Crossref] [Google Scholar]
  6. Rogers WO, Sem R, Tero T, Chim P, Lim P, Muth S, Socheat D, Ariey F, Wongsrichanalai C, , 2009. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malar J 8: 10.[Crossref] [Google Scholar]
  7. Ndiaye D, Daily JP, Sarr O, Ndir O, Gaye O, Mboup S, Wirth DF, , 2005. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Senegal. Trop Med Int Health 10: 11761179.[Crossref] [Google Scholar]
  8. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD, , 1979. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother 16: 710718.[Crossref] [Google Scholar]
  9. Smilkstein M, Sriwilaijaroen N, Kelly JX, Wilairat P, Riscoe M, , 2004. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob Agents Chemother 48: 18031806.[Crossref] [Google Scholar]
  10. Baniecki ML, Wirth DF, Clardy J, , 2007. High-throughput Plasmodium falciparum growth assay for malaria drug discovery. Antimicrob Agents Chemother 51:: 716723.[Crossref] [Google Scholar]
  11. Kurth F, Pongratz P, Belard S, Mordmuller B, Kremsner PG, Ramharter M, , 2009. In vitro activity of pyronaridine against Plasmodium falciparum and comparative evaluation of anti-malarial drug susceptibility assays. Malar J 8: 79.[Crossref] [Google Scholar]
  12. Pages F, Texier G, Pradines B, Gadiaga L, Machault V, Jarjaval F, Penhoat K, Berger F, Trape JF, Rogier C, Sokhna C, , 2008. Malaria transmission in Dakar: a two-year survey. Malar J 7: 178.[Crossref] [Google Scholar]
  13. Menard D, Madji N, Manirakiza A, Djalle D, Koula MR, Talarmin A, , 2005. Efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, chloroquine-sulfadoxine-pyrimethamine combination, and amodiaquine-sulfadoxine-pyrimethamine combination in Central African children with noncomplicated malaria. Am J Trop Med Hyg 72: 581585. [Google Scholar]
  14. Basco LK, Ringwald P, , 2001. Analysis of the key pfcrt point mutation and in vitro and in vivo response to chloroquine in Yaounde, Cameroon. J Infect Dis 183: 18281831.[Crossref] [Google Scholar]
  15. Picot S, Olliaro P, de Monbrison F, Bienvenu AL, Price RN, Ringwald P, , 2009. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar J 8: 89.[Crossref] [Google Scholar]
  16. Thomas SM, Ndir O, Dieng T, Mboup S, Wypij D, Maguire JH, Wirth DF, , 2002. In vitro chloroquine susceptibility and PCR analysis of pfcrt and pfmdr1 polymorphisms in Plasmodium falciparum isolates from Senegal. Am J Trop Med Hyg 66: 474480. [Google Scholar]
  17. Sarr O, Myrick A, Daily J, Diop BM, Dieng T, Ndir O, Sow PS, Mboup S, Wirth DF, , 2005. In vivo and in vitro analysis of chloroquine resistance in Plasmodium falciparum isolates from Senegal. Parasitol Res 97: 136140.[Crossref] [Google Scholar]
  18. Henry M, Diallo I, Bordes J, Ka S, Pradines B, Diatta B, M’Baye PS, Sane M, Thiam M, Gueye PM, Wade B, Touze JE, Debonne JM, Rogier C, Fusai T, , 2006. Urban malaria in Dakar, Senegal: chemosusceptibility and genetic diversity of Plasmodium falciparum isolates. Am J Trop Med Hyg 75: 146151. [Google Scholar]
  19. Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, Djimde AA, Kouriba B, Taylor TE, Plowe CV, , 2003. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis 187: 18701875.[Crossref] [Google Scholar]
  20. Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, Taylor TE, Plowe CV, , 2006. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med 355: 19591966.[Crossref] [Google Scholar]
  21. Brasseur P, Agnamey P, Gaye O, Cisse M, Badiane M, Vaillant M, Taylor WR, Olliaro P, , 2009. Dosing accuracy of artesunate and amodiaquine as treatment for falciparum malaria in Casamance, Senegal. Trop Med Int Health 14: 7987.[Crossref] [Google Scholar]
  22. Wellems TE, Plowe CV, , 2001. Chloroquine-resistant malaria. J Infect Dis 184: 770776.[Crossref] [Google Scholar]
  23. Ekland EH, Fidock DA, , 2008. In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes. Int J Parasitol 38: 743747.[Crossref] [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2010.09-0470
Loading
/content/journals/10.4269/ajtmh.2010.09-0470
Loading

Data & Media loading...

  • Received : 13 Aug 2009
  • Accepted : 24 Oct 2009

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error